Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC)

Journal of Immunotherapy

Volumn 30, Issue 7, 2007, Pages 780-786

  Buti, Sebastiano ^a,c   Brighenti, Matteo ^a   Bongiovanni, Cristiano ^b   Buzio, Carlo ^b   Chiesa, Matteo Dalla ^a   Alberici, Federico ^b   Passalacqua, Rodolfo ^a  

^a Oncology Division   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UO Oncologia   (Italy)

Author keywords

Chemoimmunotherapy; Chemotherapy; Metastatic renal cell cancer

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; CISPLATIN; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 2; THALIDOMIDE;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INJECTION SITE REACTION; KIDNEY CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PRIORITY JOURNAL; SENSORY NEUROPATHY; SHIVERING; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34748837365     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31814fb2ec     Document Type: Article

References (43)

1. Stewart SL, King JB, Thompson TD, et al. Cancer mortality surveillance - United States, 1990-2000. MMWR Surveill Summ. 2004;53:1-108.
2. Mickisch G, Carballido J, Hellsten S, et al. Guidelines on renal cell cancer. Eur Urol. 2001;40:252-255.
3. Montie JE, Steward BH, Straffon BA, et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977;117:272-275.
4. Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;8:1928-1935.
5. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
6. Buzio C, Andrulli S, Santi R, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer. 2001;92:2286-2296.
7. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
8. Yagoda A. Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol. 1989;7:199-206.
9. Buzaid AC, Todd MB. Therapeutic options in renal cell carcinoma. Semin Oncol. 1989;16(1suppl 1):12-19.
10. Lilleby W, Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol. 2005;23:175-179.
11. Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol. 2005;16:7-15.
12. Passalacqua R, Buti S, Tomasello G, et al. Immunotherapy options in metastatic renal cell cancer: where we are and we are going. Expert Rev Anticancer Ther. 2006;6:1459-1472.
13. Yang JC, Haworth L, Sherry RM, et al. A randomised trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
14. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.
15. Escudier B, Eisen T, Stadlre WM, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med. 2007;356:125-134.
16. Rini BI. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep. 2006;8:85-89.
17. Passalacqua R, Buzio C, Labianca R, et al. Maintenance biotherapy for metastatic renal cell cancer with IL-2 and IFN-α: a phase III, randomised, multicentre trial. Ann Oncol. 2004; Oct 15(suppl): iii111-iii112, Abstr 4170: 29th European Society for Medical Oncology (ESMO) Congress, 29 October-2 November 2004, Wien, Austria.
18. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,20-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29-34.
19. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995;22:42-60.
20. Hartmann JT, Bokemeyer C. Chemotherapy for renal carcinoma. Anticancer Res. 1999;19:1541-1543.
21. Kish JA, Wolf M, Crawford ED, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal carcinoma: a Southwest Oncology Group Study. Cancer. 1994;74:916-919.
22. Heineman V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CLM cells by 2, 2-difluoro-2-deoxycytidine. Mol Pharmacol. 1990;38:567-572.
23. Baker CH, Banzon J, Bollinger JM, et al. 2-deoxy-2-methylenecytidineand 2-deoxy-2,2-difluorocytidine 5-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem. 1991;34:1879-1884.
24. Abbruzzese JL, Grunewald F, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
25. Huang P, Chubb S, Hertel LW, et al. Action of 2,2-difluoro 2-deoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110-6117.
26. Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro 2-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res. 1998;4:2811-2818.
27. Plunkett W, Huang P, Xu Y-Z, et al. Gemcitabine: metabolism, mechanism of action and self-potentiation. Semin Oncol. 1995;22:3-10.
28. Peters GJ, Van Der Wilt CL, Van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther. 2000;87:227-253.
29. Schulz L, Schalhorn A, Wilmanns W, et al. Synergistic interaction of Gemcitabine and 5-fluorouracil in colon cancer cells. Proc Am Soc Clin Oncol. 1998;17:251, Abstract 965.
30. Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419-2426.
31. Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Annal Oncol. 1993;4:331-332.
32. De Mulder PH, Weissbach L, Jakse G, et al. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol. 1996;37:491-495.
33. Desai AA, Vogelzang NJ, Rini BI, et al. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629-1636.
34. George CM, Vogelzang NJ, Rini BI, et al. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol. 2002;13:116-120.
35. Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer. 2004;91:1763-1768.
36. Stadler WM, Halabi S, Rini B, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006;107:1273-1279.
37. Van Veldhuizen PJ, Hussey M, Lara PN, et al. A phase II study of IV gemcitabine (G) and oral capecitabine (C) in patients (pts) with advanced renal cell cancer (RCC): results of Southwest Oncology Group study 0312. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement) 2007:15562.
38. Mani S, Vogelzang NJ, Bertucci D, et al. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly Gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001;92:1567-1576.
39. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer. 2005;103:553-558.
40. Plate JM, Plate AE, Shott S, et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 2005;54:915-925.
41. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
42. Trotti A, Colevas AD, Setser A, et al. CTCAE Version 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181.
43. Correale P, Cusi MG, Tsang KY, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005;23:8950-8958.